The aforementioned MYC‐PRMT5‐RNA splicing axis suggests that inhibiting PRMT5 and its associated RNA splicing regulatory network may be an attractive and alternative strategy to target spliceosome‐mutant leukemias. Here, PRMT5 is linked to leukemia.